Similarly, hsa-miR-9 is a negative regulator of cardiac hypertrophy, suppresses myocardin expression and ameliorates cardiac function, is significantly lower in hypertensive patients compared to healthy individuals, positively correlates with left ventricular mass, and may serve as a potential marker or indicator of target organ damage (43, 44). Here, MYOCD is linked to cardiac hypertrophy.